Procter & Gamble Health Past Earnings Performance
Past criteria checks 2/6
Procter & Gamble Health has been growing earnings at an average annual rate of 12%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 8.3% per year. Procter & Gamble Health's return on equity is 28.1%, and it has net margins of 18.3%.
Key information
12.0%
Earnings growth rate
12.0%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 8.3% |
Return on equity | 28.1% |
Net Margin | 18.3% |
Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Procter & Gamble Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 12,370 | 2,267 | 3,092 | 0 |
30 Sep 23 | 12,370 | 2,314 | 2,845 | 0 |
30 Jun 23 | 12,296 | 2,295 | 2,811 | 0 |
31 Mar 23 | 12,243 | 2,408 | 3,030 | 0 |
31 Dec 22 | 11,712 | 2,328 | 2,873 | 0 |
30 Sep 22 | 11,392 | 2,008 | 2,807 | 0 |
30 Jun 22 | 11,144 | 1,925 | 2,776 | 0 |
31 Mar 22 | 11,039 | 1,853 | 2,548 | 0 |
31 Dec 21 | 10,552 | 1,499 | 2,473 | 0 |
30 Sep 21 | 10,176 | 1,729 | 2,372 | 0 |
30 Jun 21 | 10,087 | 1,768 | 2,426 | 0 |
31 Mar 21 | 9,219 | 1,884 | 2,690 | 0 |
31 Dec 20 | 9,308 | 2,191 | 2,577 | 0 |
30 Sep 20 | 9,274 | 1,894 | 2,545 | 0 |
30 Jun 20 | 8,886 | 1,659 | 2,473 | 0 |
31 Mar 20 | 9,237 | 1,645 | 1,171 | 0 |
31 Dec 19 | 9,266 | 1,588 | 1,242 | 0 |
30 Sep 19 | 8,942 | 1,340 | 2,438 | 0 |
30 Jun 19 | 8,952 | 1,394 | 2,424 | 0 |
31 Mar 19 | 8,819 | 1,281 | 2,428 | 0 |
31 Dec 18 | 8,490 | 1,017 | 2,428 | 0 |
30 Sep 18 | 12,290 | 1,349 | 2,914 | 0 |
30 Jun 18 | 12,087 | 1,140 | 2,913 | 0 |
31 Mar 18 | 11,762 | 1,018 | 2,826 | 0 |
31 Dec 17 | 6,981 | 610 | 2,076 | 0 |
30 Sep 17 | 10,523 | 828 | 2,387 | 0 |
30 Jun 17 | 10,088 | 797 | 2,360 | 0 |
31 Mar 17 | 10,177 | 823 | 1,546 | 0 |
31 Dec 16 | 9,926 | 791 | 2,347 | 0 |
30 Sep 16 | 9,810 | 723 | 2,295 | 0 |
30 Jun 16 | 9,681 | 572 | 1,835 | 0 |
31 Mar 16 | 9,589 | 562 | 1,282 | 0 |
31 Dec 15 | 9,383 | 536 | 2,107 | 0 |
30 Sep 15 | 9,148 | 401 | 3,033 | 110 |
30 Jun 15 | 8,798 | 451 | 3,006 | 110 |
31 Mar 15 | 8,712 | 493 | 2,957 | 110 |
31 Dec 14 | 8,662 | 432 | 1,889 | 0 |
30 Sep 14 | 8,544 | 516 | 2,730 | 86 |
30 Jun 14 | 8,409 | 498 | 2,684 | 86 |
31 Mar 14 | 8,082 | 455 | 2,673 | 86 |
31 Dec 13 | 7,965 | 559 | 2,646 | 86 |
30 Sep 13 | 7,599 | 665 | 2,267 | 50 |
30 Jun 13 | 7,404 | 765 | 2,224 | 50 |
Quality Earnings: 500126 has a high level of non-cash earnings.
Growing Profit Margin: 500126's current net profit margins (18.3%) are lower than last year (19.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 500126's earnings have grown by 12% per year over the past 5 years.
Accelerating Growth: 500126's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 500126 had negative earnings growth (-2.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).
Return on Equity
High ROE: 500126's Return on Equity (28.1%) is considered high.